Percutaneous Coronary Intervention: Safety of Methotrexate and Its Possible Benefits on Restenosis After Bare-Metal Stent Deployment

Abstract

BackgroundPercutaneous coronary intervention (PCI) revolutionized treatment of coronary artery disease. Drug-eluting stents are effective and safe but their cost is high, especially for some countries. The primary objective was to evaluate the safety of methotrexate (MTX) in patients who underwent PCI and the secondary goal was to evaluate the possibility that MTX has an impact on restenosis.MethodsThis was a transversal, prospective and descriptive study that recruited 16 patients in whom PCI was planned. MTX was administered to patients at a dose of 5 mg/week for 2 weeks before PCI and 8 weeks after PCI. Bare-metal stent (BMS) deployment was performed according to standard practice. Patients were monitored clinically every 15 days during the first 2 months after the procedure and monthly until 9 months after PCI.ResultsThere were no immediate or late complications associated with PCI. Adverse events and side effects due to MTX occurred in three patients (prevalence 18.7%). These side effects are classified as minor complications. MTX was not discontinued due to these side effects. There were no reported cases of clinical restenosis.ConclusionsMTX was safe in the study population and raised the possibility that a low-cost drug may have positive effects on restenosis after BMS implantation. However, studies with larger sample sizes and other imagine modalities (intravascular ultrasound and/or optical coherence tomography) are required to confirm this hypothesis.

Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates

“…A pilot study evaluated the safety of methotrexate therapy (5 mg/week) in 16 patients with coronary artery disease undergoing percutaneous coronary intervention (PCI), started 2 weeks prior to the procedure and continued for 8 weeks after the procedure. No major safety signals were observed during this period [ 32 ]. A RCT, the TETHYS trial, evaluated the role of methotrexate in patients with ST segment elevation myocardial infarction (STEMI).…”

Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study

“…Percutaneous coronary intervention (PCI) is one of the most effective therapies for coronary heart disease. With the improvement of interventional technique of coronary artery in recent years, the number of percutaneous coronary intervention was increasing [ 1 – 3 ]. Treating complicated coronary artery disease, especially chronic occlusion disease (CTO), is not a difficult problem presently [ 4 ].…”

In-stent Restenosis after Drug-eluting Stent Implantation in Rheumatoid Arthritis: Possible Protective Effect of Methotrexate

“…An intravenous injection of MTX resulted in the reduction of in-stent neoatherosclerosis in an animal model 5 . Further, a clinical study suggested the positive effect of oral MTX on ISR after BMS implantation 6 . However, little is known about the effect of oral MTX on ISR after DES implantation.…”